Substractive single label comparative hybridization

• US 7,507,539 B2
• Filed: 07/30/2007
• Issued: 03/24/2009
• Est. Priority Date: 07/30/2007
• Status: Expired due to Fees

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Strom, Charles M., Owen, Renius
• Primary Examiner(s): WHISENANT, ETHAN C
• Application Number:
  US11/830,768
• Publication Number:
  US 20090035757A1
• Time in Patent Office: 603 Days
• Field of Search: 435/6, 536/22.1, 536/23.1, 536/24.3
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 2521/531 Glycosylase
• CPC Class Codes: C12Q 2563/107 fluorescence
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides

Abstract

Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities.

Claims

1. A method of determining genomic abnormalities in a test sample of genomic nucleic acid, comprising:

amplifying genomic sequence from a test sample and amplifying genomic sequence from a reference sample nucleic acids wherein one of the amplification reactions is conducted using dUTP and not dTTP and the other is conducted using dTTP and not dUTP;

hybridizing to a genomic nucleic acid array a solution comprising the amplified test sample and amplified reference sample; and

determining the relative amount of hybridized test and reference nucleic acids bound to the array, wherein a difference in the relative amount of hybridized test and reference nucleic acids bound to the array identifies the presence of a genomic abnormality.

2. The method of claim 1 wherein said amplified nucleic acid is labeled with a detectable label.

3. The method of claim 1 wherein said amplified test and reference samples of genomic nucleic acid are labeled with the same detectable label.

4. The method of claim 2 wherein said detectable label is a fluorochrome.

5. The method of claim 2 wherein said detectable label is dCTP-Cy3.

6. The method of claim 2 wherein said amplified nucleic acid is labeled with a detectable label by using a nucleotide labeled with a detectable label in the step of amplifying said genomic nucleic acid.

7. The method of claim 6 wherein said test and reference samples of genomic nucleic acid are amplified using the same and reference samples of genomic nucleic acid are labeled with the same nucleotide labeled with a detectable label.

8. The method of claim 7 wherein said labeled nucleotide is dCTP-Cy3.

9. The method of claim 2 wherein said step of determining the relative amount of hybridized test and reference nucleic acids bound to the array comprises:

a) determining a signal for the detectable label hybridized to the array representing the total of hybridized test and reference nucleic acid;

b) treating the hybridized nucleic acids with an enzyme that selectively degrades DNA having uracil residues;

c) determining a signal for the detectable label hybridized to the array following step b), which signal represents one of said hybridized test or reference nucleic acid; and

d) determining a signal for the other of the hybridized test or reference by using the signal from a) and c).

10. The method of claim 9 wherein said enzyme that selectively degrades DNA having uracil residues is uracil-DNA N-glycosylase (UNG).

11. The method of claim 9, wherein said test sample is obtained from a patient.

12. The method of claim 9, wherein said test sample obtained from a patient is suspected of comprising cancerous cells.

13. The method of claim 9, wherein said test sample is obtained from a prenatal specimen.

14. The method of claim 9, wherein said test sample is obtained from an embryo or fetus.

15. The method of claim 9, wherein said test sample is from an individual and the method is used to detect a genetic abnormality.

16. A method of determining differences between nucleic acid in a test sample and a reference sample comprising:

(a) contacting under hybridization conditions a test sample containing nucleic acids and a reference sample containing nucleic acids to a surface containing a plurality of nucleic acid segments each immobilized at discrete locations on the surface, wherein the test sample and the reference sample are labeled before or after hybridization with the same detectable label;

(b) determining the location and amount of the detectable label linked to nucleic acids hybridized to the surface;

(c) selectively removing either the hybridized test sample genomic nucleic acids or the hybridized reference sample genomic nucleic acids;

(d) determining the location and amount of the detectable label linked to nucleic acids hybridized to the surface following step (c); and

(e) comparing the results of step (b) to the results of step (d) to detect differences in the nucleic acids of the test sample and reference sample.

17. The method of claim 16, wherein said test nucleic acids are genomic sequences amplified from genomic DNA in a test sample sequence from a test sample and said reference nucleic acids are amplified from genomic DNA in a reference sample;

wherein one of the amplification reactions is conducted using dUTP and not dTTP and the other is conducted using dTTP and not dUTP.

18. The method of claim 17, wherein said the step of selectively removing hybridized test nucleic acids or reference nucleic acids is performed by subjecting the nucleic acids to an enzyme that selectively degrades DNA degrades DNA having uracil residues.

19. The method of claim 18, wherein said enzyme that selectively degrades DNA having uracil residues is uracil-DNA N-glycosylase (UNG).

20. The method of claim 19, wherein said nucleic acids in said test sample and said reference sample are labeled with a detectable label.

21. The method of claim 20, wherein said nucleic acids in said test sample and said reference sample are labeled with the same detectable label.

22. A method of comparing the expression of genes in a test sample versus that of a reference sample said method comprising

amplifying nucleic acid sequence from cDNA prepared from RNA of the test sample and amplifying nucleic acid sequence from cDNA prepared from RNA of the reference sample, wherein one of the amplification reactions is conducted using dUTP and not dTTP and the other is conducted using dTTP and not dUTP;

hybridizing to the nucleic acid array a solution comprising the amplified test sample and amplified reference sample;

performing a first scan to determine a signal for the detectable label hybridized to the array representing the total of hybridized test and reference nucleic acid;

treating the hybridized nucleic acids with an enzyme that selectively degrades DNA having uracil residues;

performing a second scan to determine a signal for the detectable label hybridized to the array following said treating the hybridized nucleic acids with an enzyme that selectively degrades DNA having uracil residues; and

comparing the signal from said first scan with the signal from said second scan to determine differences between said test sample and said reference sample in the expression of at least one gene.